Physiological platelet receptors and hemostatic interfaces

Physiological platelet receptors and hemostatic interfaces refer to the collective system of surface proteins and signaling pathways that enable platelets to adhere to damaged blood vessels and aggregate to form clots. This system includes critical receptors such as the Glycoprotein Ib-IX-V complex, which initiates adhesion by binding to von Willebrand factor, and Glycoprotein VI, which serves as the primary signaling receptor for collagen (Source: StatPearls, Physiology, Platelet). The final common pathway of platelet activation involves the conformational change of Integrin alpha-IIb/beta-3 (GP IIb/IIIa), allowing it to bind fibrinogen and cross-link platelets into a stable plug (Source: UniProt, ITGA2B). While these interfaces are vital for normal hemostasis, their pathological activation leads to arterial thrombosis, causing life-threatening conditions like myocardial infarction and ischemic stroke (Source: PubMed, PMID: 30231147). Consequently, this interface is a major focus of cardiovascular pharmacology, with drugs like P2Y12 inhibitors (e.g., Clopidogrel) and GP IIb/IIIa antagonists (e.g., Abciximab) designed to modulate these interactions (Source: PubChem). This entry represents a broad physiological category rather than a single therapeutic target.

Other names

Platelet surface receptorsPlatelet adhesion receptorsPlatelet activation receptorsHemostatic interface proteinsPlatelet-vessel wall interface

Antiplatelet agents target this interface by inhibiting specific receptors such as P2Y12 or GP IIb/IIIa, or by blocking enzymes like COX-1 to prevent the synthesis of activating factors like thromboxane A2.